John Poulin

Contact John Poulin

John Poulin

John is a healthcare expert who works with organizations to design new strategies that will help them achieve long-term growth, build innovation capabilities, define new operating models and manage enterprisewide transformation.

About John

As a leader at Innosight, Huron’s strategy and innovation business, John helps organizations prepare for and generate long-term growth through more strategic resource allocation, internal innovation capabilities and new operating models. He also has significant expertise in merger and acquisition (M&A) advisory, guiding organizations from initial opportunity identification to post-merger integration.

Throughout his career, John has advised executive teams across the healthcare and life sciences value chain, including payors, providers, medical device, pharmaceutical and healthcare information technology organizations. Much of his recent work has focused on how payors and providers can better collaborate to create new care delivery models, economic models, and better physical and digital consumer experiences.

Beyond healthcare, John has worked with a range of global automotive, defense and energy organizations, helping cyclical, capital intensive firms evolve their core business models and drive new growth simultaneously.

Before joining Innosight, John worked in Oliver Wyman’s health and life sciences practice where he developed product and portfolio strategies for pharmaceutical clients and helped health insurance companies transform from fee-for-service to fee-for-value business models. Prior to that he was a senior executive at Genzyme.

Areas of Expertise

  • Enterprise Strategy
  • Innovation and Commercialization
  • Strategic Programming


  • Healthcare
  • Consumer Products
  • Life Sciences
  • Technology Media and Telecommunications

Education & Certifications

  • B.A., Wesleyan University


  • After the Breakups: Big Payers Find Vertical Love in New Faces

    Read More

    In rapid succession at the end of 2018, CVS closed its $70 billion acquisition of Aetna and Cigna closed its $67 billion acquisition of Express Scripts.

View All

Our Experts

Learn more about Huron's experts.

Learn More


Join Our Talent Community

Learn More

We use cookies on our website to provide you with a more personalized digital experience, enable website functionality and understand the performance of our site. You may review our Privacy Statement and our Cookies Policy. By using this site you agree to our use of cookies. I Accept